Cargando…

Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia

BACKGROUND: Single cell network profiling (SCNP) utilizing flow cytometry measures alterations in intracellular signaling responses. Here SCNP was used to characterize Acute Myeloid Leukemia (AML) disease subtypes based on survival, DNA damage response and apoptosis pathways. METHODOLOGY AND PRINCIP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosen, David B., Putta, Santosh, Covey, Todd, Huang, Ying-Wen, Nolan, Garry P., Cesano, Alessandra, Minden, Mark D., Fantl, Wendy J.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928279/ https://www.ncbi.nlm.nih.gov/pubmed/20811632 http://dx.doi.org/10.1371/journal.pone.0012405

Ejemplares similares

Functional Characterization of FLT3 Receptor Signaling Deregulation in Acute Myeloid Leukemia by Single Cell Network Profiling (SCNP)
por: Rosen, David B., et al.
Publicado: (2010)

Signaling changes in the stem cell factor–AKT-S6 pathway in diagnostic AML samples are associated with disease relapse
por: Kornblau, S M, et al.
Publicado: (2011)

Association of Reactive Oxygen Species-Mediated Signal Transduction with In Vitro Apoptosis Sensitivity in Chronic Lymphocytic Leukemia B Cells
por: Palazzo, Adam L., et al.
Publicado: (2011)

Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression
por: Niapour, M, et al.
Publicado: (2012)

Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase
por: Chakraborty, S, et al.
Publicado: (2013)

JAK-STAT in Early Hematopoiesis and Leukemia
por: Fasouli, Eirini Sofia, et al.
Publicado: (2021)

Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia
por: Kim, Peter S., et al.
Publicado: (2008)

Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients
por: Thiant, S, et al.
Publicado: (2017)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients
por: Thiant, S., et al.
Publicado: (2020)

Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia
por: Chakraborty, Sandip N., et al.
Publicado: (2016)

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
por: Chung, Woonbok, et al.
Publicado: (2019)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

Acute Myelogenous Leukemia and Febrile Neutropenia
por: Herbers, Alexandra, et al.
Publicado: (2009)

Trifolium Repens Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 Pathway
por: Sarno, Federica, et al.
Publicado: (2020)

Leelamine Modulates STAT5 Pathway Causing Both Autophagy and Apoptosis in Chronic Myelogenous Leukemia Cells
por: Jung, Young Yun, et al.
Publicado: (2022)

Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome
por: Chakraborty, Rajshekhar, et al.
Publicado: (2014)

Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder
por: Maerki, J., et al.
Publicado: (2014)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
por: Ferrari, Anna, et al.
Publicado: (2023)

Applications of Microarray Technology to Acute Myelogenous Leukemia
por: Goswami, Rashmi S., et al.
Publicado: (2008)

Biomarkers for determining the prognosis in chronic myelogenous leukemia
por: Sweet, Kendra, et al.
Publicado: (2013)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
por: Janani, Gopalarethinam, et al.
Publicado: (2023)

The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor–Treated Chronic Myelogenous Leukemia
por: Lavoie, Declan C T, et al.
Publicado: (2019)

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature
por: Bader, Gilbert, et al.
Publicado: (2019)

The JAK-STAT pathway in hypertrophic stress signaling and genomic stress response
por: Wagner, Michael A., et al.
Publicado: (2012)

Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity
por: Ptacek, Jason, et al.
Publicado: (2021)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

In vitro and in vivo modelling of mutant JAK3/STAT5 signaling in leukemia
por: Omari, Sofia A., et al.
Publicado: (2023)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient
por: Beaud, Jenny, et al.
Publicado: (2018)

Overexpression of lung resistance-related protein and P-glycoprotein and response to induction chemotherapy in acute myelogenous leukemia
por: Tsuji, Kazue, et al.
Publicado: (2012)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
por: Long, Bing, et al.
Publicado: (2011)

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_11bucc8kk4lc16a2qq0rpscgt9